Intravitreous ranibizumab (lucentis) for radiation maculopathy

Arch Ophthalmol. 2010 Feb;128(2):249-52. doi: 10.1001/archophthalmol.2009.376.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Brachytherapy / adverse effects*
  • Choroid Neoplasms / radiotherapy
  • Female
  • Fluorescein Angiography
  • Humans
  • Injections
  • Macula Lutea / radiation effects*
  • Macular Edema / drug therapy
  • Macular Edema / etiology
  • Male
  • Melanoma / radiotherapy
  • Middle Aged
  • Palladium / adverse effects
  • Radiation Injuries / drug therapy*
  • Radiation Injuries / etiology
  • Radioisotopes / adverse effects
  • Ranibizumab
  • Retinal Diseases / drug therapy*
  • Retinal Diseases / etiology
  • Retinal Hemorrhage / drug therapy
  • Retinal Hemorrhage / etiology
  • Retinal Neovascularization / drug therapy
  • Retinal Neovascularization / etiology
  • Tomography, Optical Coherence
  • Visual Acuity
  • Vitreous Body

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Radioisotopes
  • Palladium
  • Ranibizumab

Associated data

  • ClinicalTrials.gov/NCT00750399